secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023234
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study
-----------------------------------------------------------------------

- Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.
- Cash, equivalents & short-term investments total $116M as of Sept 30, 2022.
- Over 80% enrollment in pivotal STRIDE study for PMM with mtDNA defects; topline data expected Q4 2023.
- Positive Phase 1b results in LC-FAOD patients; planning Phase 2 study.
- FDA and EMA confirmed positive data from STRIDE/STRIDE AHEAD could support registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/0000950170-22-023234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/rphm-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer